GLP-1 for diabetes vs weight loss: same drug, different rules

TLDR. Ozempic and Wegovy are the same molecule (semaglutide) at different maximum doses: Ozempic at 2.0 mg weekly for type 2 diabetes, Wegovy at 2.4 mg weekly for obesity. Mounjaro and Zepbound are the same molecule (tirzepatide) at the same maximum dose, with different FDA indications. Insurance coverage, prior authorization, and pharmacy fulfillment differ between the labels. Patients with type 2 diabetes plus obesity usually qualify for the diabetes label (often the better-covered option). The clinical effect on weight is similar across labels at equivalent doses.

This trips up almost everyone the first time they look at GLP-1s seriously: Ozempic and Wegovy are the same drug (semaglutide). Mounjaro and Zepbound are the same drug (tirzepatide). They're sold under different names with different doses and different indications.

The split matters because insurance, regulatory framing and program eligibility all hinge on which name appears on the prescription.

The basic mapping

The differences that matter

Dose ceilings. Wegovy goes up to 2.4mg/week of semaglutide; Ozempic tops out at 2.0mg. Zepbound and Mounjaro share the same 2.5-15mg dose range. For weight loss, the higher Wegovy dose is meaningful, some patients need it.

Insurance formulary. Most US commercial plans cover the diabetes brand for diabetes patients (with prior auth) and the weight-loss brand for obesity patients (with prior auth, BMI requirements). Medicare and many Medicaid plans cover the diabetes brands but not the weight-loss brands. This is a meaningful gap for older or lower-income patients.

Off-label prescribing. Many telehealth programs prescribe Ozempic or Mounjaro off-label for weight loss. This is legal and common, but creates two complications:

• Insurance may deny because the diagnosis on file is weight loss, not diabetes
• Some pharmacies will not fill a Mounjaro prescription for a non-diabetic patient even if the prescription is valid

Manufacturer savings cards. Both Novo and Lilly offer commercial-only patient assistance cards that reduce branded GLP-1 cost. The cards are tied to the brand name; you cannot use a Wegovy card for an Ozempic prescription, even though it's the same drug.

Compounded versions. Compounded semaglutide and tirzepatide are not branded as either diabetes or weight-loss products. They are simply "compounded semaglutide" prescribed for whatever indication the prescriber documents. This regulatory ambiguity has been a feature for cash-pay weight-loss programs and a target for branded manufacturers' lawsuits.

What this means for program choice

If you have diabetes:

• Insurance-coverage paths through Ozempic, Mounjaro or Trulicity are usually the cheapest option. Programs like 9amHealth, Knownwell, and Form Health handle this well.
• You typically get the diabetes brand at diabetes-tier copay (often $25-50/mo).
• If you also have obesity-grade BMI, you may qualify for both indications, which expands prescription flexibility.

If you don't have diabetes but do have obesity:

• Wegovy or Zepbound is your indicated drug.
• Insurance coverage requires obesity-grade BMI (≥30, or ≥27 with comorbidity) plus prior auth.
• Cash-pay branded options: NovoCare for Wegovy ($149-$299/mo), LillyDirect for Zepbound vials ($299-$449/mo).
• Compounded paths through programs like Mochi and Henry Meds remain cheapest at $178-$297/mo all-in.

If you're prediabetic (HbA1c 5.7-6.4%):

• You're in the gray zone. Some plans cover Wegovy/Zepbound for prediabetes + obesity; many do not. Check formulary.
• 9amHealth's cardiometabolic model is purpose-built for this scenario and worth considering.

Why is the same drug priced differently?

The cynical answer: because the manufacturer can. Novo Nordisk launched Wegovy at a higher price than Ozempic primarily because the obesity indication has lower insurance penetration and higher cash-pay willingness. The clinical molecule, the manufacturing process, and the safety profile are identical.

Generic semaglutide arrival (late 2026 to early 2027) will collapse this brand-based pricing distinction over time. Generic semaglutide will likely be priced as a single product with both diabetes and weight-loss indications.

The simple decision rule

Ask your program which specific brand they're prescribing and whether your insurance covers it for your diagnosis. Not "do you take insurance?" but "for my BMI of 32 and no diabetes, will you prescribe Wegovy through my BlueCross plan and what's the realistic copay?" Programs that can answer this in concrete terms (Form Health, 9amHealth, PlushCare) will save you weeks of insurance back-and-forth. Programs that hand-wave through it will not.

Frequently asked questions

Are Ozempic and Wegovy the same drug?

Same molecule (semaglutide), different labels. Ozempic is FDA-approved for type 2 diabetes with a maximum dose of 2.0 mg weekly. Wegovy is FDA-approved for obesity (and cardiovascular risk reduction in established CVD) with a maximum dose of 2.4 mg weekly. The clinical effect at equivalent doses is identical; the indication on the prescription determines insurance coverage and pharmacy fulfillment.

Are Mounjaro and Zepbound the same drug?

Same molecule (tirzepatide), different labels. Both top out at 15 mg weekly. Mounjaro is FDA-approved for type 2 diabetes; Zepbound for obesity and (since December 2024) moderate-to-severe obstructive sleep apnea in patients with obesity. Coverage and prior authorization criteria differ between the labels.

If I have type 2 diabetes and obesity, which label should I be on?

Usually the diabetes label, because commercial insurance coverage is broader for T2D and Medicare covers Ozempic for diabetes but not Wegovy for obesity (except in established CVD). Your prescriber writes the prescription against the diagnosis that drives coverage; the underlying drug is the same molecule.

Can I switch from Wegovy to Ozempic to save on cost?

Only if you have type 2 diabetes or prediabetes that qualifies. Ozempic is not approved for obesity alone, and prescribing it for that indication is off-label. The two products are not interchangeable from a coverage standpoint, even though they are the same molecule. Pharmacy benefit managers track NDC, not chemistry.

Why do Mounjaro and Zepbound exist as separate products?

Regulatory and commercial strategy. Eli Lilly launched Mounjaro first for T2D in 2022 because diabetes endpoints were easier to file and coverage was broader. Zepbound launched in late 2023 with the obesity indication. Holding two labels lets Lilly run separate prior authorization criteria, copay cards, and marketing campaigns for each market.